Single-dose of BNT162b2 vaccine may not be protective without prior SARS-CoV-2 infection

By | March 1, 2021
A new study by researchers at Imperial College London, UK, discusses the effect of a vaccine dose, specifically the BNT162b2 candidate (also known as the ‘Pfizer-BioNTech’ vaccine), on neutralizing antibody titers in individuals who have already been infected with the virus.